ARS Pharmaceuticals, Inc.

Contributing Author

Recent Articles by ARS Pharmaceuticals, Inc.

May-07	ARS Pharmaceuticals' neffy (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms SPRY GlobeNewswire
May-05	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results SPRY GlobeNewswire
May-02	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians SPRY GlobeNewswire